nach oben

Annals of Nuclear Medicine

Erschienen in:

20.06.2018 | Original Article

Clinical application of ^99mTc-HYNIC-TOC SPECT/CT in diagnosing and monitoring of pancreatic neuroendocrine neoplasms

verfasst von: Junyan Xu, Yi Li, Xiaoping Xu, Jiangang Zhang, Yingjian Zhang, Xianjun Yu, Dan Huang

Erschienen in: Annals of Nuclear Medicine | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Objective

Our aim of this research was to determine the value of SPECT/CT with ^99mTc-HYNIC-TOC for evaluation of the pancreatic masses which were suspected as neuroendocrine neoplasms and follow-up of patients with pancreatic neuroendocrine neoplasms.

Methods

We retrospectively analyzed 184 patients who performed ^99mTc-HYNIC-TOC SPECT/CT. All the patients were divided into two groups: one for assessment of diagnostic efficiency for pancreatic suspected masses (n = 140) and another for monitoring recurrence after surgery (n = 44). The image findings acquired at 2 h postinjection were compared to final diagnoses from pathological results and clinical follow-up. Then, the correlation between ratios of tumor-to-background (TBR) and tumor grade was analyzed.

Results

In group 1, 95/140 (67.9%) patients were confirmed as neuroendocrine neoplasms including 85 neuroendocrine tumors and 10 neuroendocrine carcinomas. Patient-based analysis showed that the sensitivity, specificity and accuracy of diagnosing neuroendocrine neoplasms with SPECT/CT were 81.1, 84.4 and 82.1%. There was significant difference of TBRs among G1, G2 and G3 (F = 3.175, P = 0.048). In group 2, 22/44 (50.0%) patients occurred metastasis mainly in liver. The sensitivity, specificity and accuracy of monitoring recurrence were 87.0, 100 and 93.2%.

Conclusions

^99mTc-HYNIC-TOC SPECT/CT is a reliable method of diagnosing and monitoring of pancreatic neuroendocrine neoplasms, especially neuroendocrine tumors.

Rust E, Hubele F, Marzano E, Goichot B, Pessaux P, Kurtz JE, et al. Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice. Cancer Imaging. 2012;12:173 – 84.CrossRefPubMedPubMedCentral

Sun J. Pancreatic neuroendocrine tumors. Intractable Rare Dis Res. 2017;6:21–8.CrossRefPubMedPubMedCentral

D’Haese JG, Tosolini C, Ceyhan GO, Kong B, Esposito I, Michalski CW, et al. Update on surgical treatment of pancreatic neuroendocrine neoplasms. World J Gastroenterol. 2014;20:13893–8.CrossRefPubMedPubMedCentral

Balachandran A, Tamm EP, Bhosale PR, Patnana M, Vikram R, Fleming JB, et al. Pancreatic neuroendocrine neoplasms: diagnosis and management. Abdom Imaging. 2013;38:342–57.CrossRefPubMed

Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836 – 46.CrossRefPubMed

Olsen JO, Pozderac RV, Hinkle G, Hill T, O’Dorisio TM, Schirmer WJ, et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med. 1995;25:251 – 61.CrossRefPubMed

Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, et al. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med. 2001;42:1134–8.PubMed

Pfeifer A, Knigge U, Binderup T, Mortensen J, Oturai P, Loft A, et al. 64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-head comparison with 111In-DTPA-octreotide in 112 patients. J Nucl Med. 2015;56:847 – 54.CrossRefPubMed

Melo IB, Ueda LT, Araujo EB, Muramoto E, Barboz MF, Mengatti J, et al. Tecnetium-99m as alternative to produce somatostatin-labeled derivatives: comparative biodistribution evaluation with 111In-DTPA-octreotide. Cell Mol Biol (Noisy-le-grand). 2010;56:31–6.

10.

Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med. 2000;27:1318–25.CrossRefPubMed

11.

Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather SJ, et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med. 2003;44:708 – 16.PubMed

12.

Hubalewska-Dydejczyk A, Fross-Baron K, Mikolajczak R, Maecke HR, Huszno B, Pach D, et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experience. Eur J Nucl Med Mol Imaging. 2006;33:1123–33.CrossRefPubMed

13.

Bangard M, Behe M, Guhlke S, Otte R, Bender H, Maecke HR, et al. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-d-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-d-Phe1-octreotide. Eur J Nucl Med. 2000;27:628 – 37.CrossRefPubMed

14.

Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide. J Nucl Med. 2000;41:1114–9.PubMed

15.

Kim JY, Hong SM, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol. 2017;29:11 – 6.CrossRefPubMed

16.

Trogrlic M, Tezak S. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors. Nucl Med Rev Cent East Eur. 2016;19:74–80.CrossRefPubMed

17.

Qiao Z, Zhang J, Jin X, Huo L, Zhu Z, Xing H, et al. 99mTc-HYNIC-TOC imaging in the evaluation of pancreatic masses which are potential neuroendocrine tumors. Clin Nucl Med. 2015;40:397–400.CrossRefPubMed

18.

de la Cueva L, Lloro P, Sangros MJ, Lopez Velez L, Navarro P, Sarria L, et al. Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy. Clin Transl Oncol. 2017;19:915–20.CrossRefPubMed

19.

Sepulveda-Mendez J, de Murphy CA, Pedraza-Lopez M, Murphy-Stack E, Rojas-Bautista JC, Gonzalez-Trevino O. Specificity and sensitivity of (9)(9)mTc-EDDA/HYNIC-Tyr(3)-octreotide ((9)(9)mTc-TOC) for imaging neuroendocrine tumors. Nucl Med Commun. 2012;33:69–79.CrossRefPubMed

20.

Garai I, Barna S, Nagy G, Forgacs A. Limitations and pitfalls of 99mTc-EDDA/HYNIC-TOC (Tektrotyd) scintigraphy. Nucl Med Rev Cent East Eur. 2016;19:93 – 8.CrossRefPubMed

21.

Peter L, Sanger J, Hommann M, Baum RP, Kaemmerer D. Molecular imaging of late somatostatin receptor-positive metastases of renal cell carcinoma in the pancreas by 68 Ga DOTATOC PET/CT: a rare differential diagnosis to multiple primary pancreatic neuroendocrine tumors. Clin Nucl Med. 2014;39:713–6.CrossRefPubMed

22.

Niu N, Mao X, Jing H, Li F. Parathyroid hyperplasia shown on (99 m)Tc-HYNIC-TOC scan. Clin Nucl Med. 2013;38:294–6.CrossRefPubMed

23.

Morgat C, Velayoudom-Cephise FL, Schwartz P, Guyot M, Gaye D, Vimont D, et al. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1. Eur J Nucl Med Mol Imaging. 2016;43:1258–66.CrossRefPubMed

24.

Hasegawa S, Kobayashi N, Tokuhisa M, Goto A, Takano S, Takada Y, et al. Clinical usefulness of somatostatin receptor scintigraphy in japanese patients with gastroenteropancreatic neuroendocrine tumors. Digestion. 2017;96:13–20.CrossRefPubMed

25.

Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, et al. Comparison of 68 Ga-DOTANOC and 68 Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54:364–72.CrossRefPubMed

26.

Panagiotidis E, Alshammari A, Michopoulou S, Skoura E, Naik K, Maragkoudakis E, et al. Comparison of the impact of 68 Ga-DOTATATE and 18F-FDG PET/CT on clinical management in patients with neuroendocrine tumors. J Nucl Med. 2017;58:91–6.CrossRefPubMed

27.

Deroose CM, Hindie E, Kebebew E, Goichot B, Pacak K, Taieb D, et al. Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions. J Nucl Med. 2016;57:1949–56.CrossRefPubMed

28.

Madrzak D, Mikolajczak R, Kaminski G. Influence of PET/CT 68 Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT. Nucl Med Rev Cent East Eur. 2016;19:88–92.CrossRefPubMed

Titel: Clinical application of 99mTc-HYNIC-TOC SPECT/CT in diagnosing and monitoring of pancreatic neuroendocrine neoplasms
verfasst von: Junyan Xu
Yi Li
Xiaoping Xu
Jiangang Zhang
Yingjian Zhang
Xianjun Yu
Dan Huang
Publikationsdatum: 20.06.2018
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine / Ausgabe 7/2018
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-018-1266-8

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2018

Optimal monochromatic color combinations for fusion imaging of FDG-PET and diffusion-weighted MR images

Reconstruction/segmentation of attenuation map in TOF-PET based on mixture models

Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy

Reliable radiosynthesis of 4-[10B]borono-2-[18F]fluoro-l-phenylalanine with quality assurance for boron neutron capture therapy-oriented diagnosis

Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST

Effects of rs591323 on serotonin transporter availability in healthy male subjects